Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Sibbing

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
Lancet (London, England)|September 1, 2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trialDirk Sibbing, Dániel Aradi, Claudius Jacobshagen, et al.
Circulation|November 1, 2017
International Expert Consensus on Switching Platelet P2Y<sub>12</sub> Receptor-Inhibiting TherapiesDominick J Angiolillo, Fabiana Rollini, Robert F Storey, et al.
JACC. Cardiovascular Interventions|August 27, 2021
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration RateJochen Wöhrle, Julia Seeger, Shqipdona Lahu, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 TrialKatharina Mayer, Ralph Hein-Rothweiler, Stefanie Schüpke, et al.
Journal of the American College of Cardiology|October 1, 2013
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleedingUdaya S Tantry, Laurent Bonello, Daniel Aradi, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 15, 2020
Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesionsMarco Zimarino, Dominick J Angiolillo, George Dangas, et al.
Revista Espanola De Cardiologia (English Ed.)|December 28, 2021
Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromesShqipdona Lahu, Michael Behnes, Gjin Ndrepepa, et al.
Circulation|October 29, 2020
Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionAlp Aytekin, Gjin Ndrepepa, Franz-Josef Neumann, et al.
JAMA Cardiology|June 30, 2021
Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical TrialJ J Coughlan, Alp Aytekin, Shqipdona Lahu, et al.
JACC. Cardiovascular Interventions|June 17, 2019
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y<sub>12</sub> Receptor Inhibitor Treatment in Percutaneous Coronary InterventionDirk Sibbing, Daniel Aradi, Dimitrios Alexopoulos, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
Lancet (London, England)|September 1, 2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trialDirk Sibbing, Dániel Aradi, Claudius Jacobshagen, et al.
Circulation|November 1, 2017
International Expert Consensus on Switching Platelet P2Y<sub>12</sub> Receptor-Inhibiting TherapiesDominick J Angiolillo, Fabiana Rollini, Robert F Storey, et al.
JACC. Cardiovascular Interventions|August 27, 2021
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration RateJochen Wöhrle, Julia Seeger, Shqipdona Lahu, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 TrialKatharina Mayer, Ralph Hein-Rothweiler, Stefanie Schüpke, et al.
Journal of the American College of Cardiology|October 1, 2013
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleedingUdaya S Tantry, Laurent Bonello, Daniel Aradi, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 15, 2020
Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesionsMarco Zimarino, Dominick J Angiolillo, George Dangas, et al.
Revista Espanola De Cardiologia (English Ed.)|December 28, 2021
Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromesShqipdona Lahu, Michael Behnes, Gjin Ndrepepa, et al.
Circulation|October 29, 2020
Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionAlp Aytekin, Gjin Ndrepepa, Franz-Josef Neumann, et al.
JAMA Cardiology|June 30, 2021
Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical TrialJ J Coughlan, Alp Aytekin, Shqipdona Lahu, et al.
JACC. Cardiovascular Interventions|June 17, 2019
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y<sub>12</sub> Receptor Inhibitor Treatment in Percutaneous Coronary InterventionDirk Sibbing, Daniel Aradi, Dimitrios Alexopoulos, et al.
Pageof 20